CT
Celea TherapeuticsClinical-stage biotech developing deupirfenidone, a deuterated pirfenidone-derived drug for idiopathic pulmonary fibrosis, spun out of PureTech Health.
4 Pulse stories
O
OneMedNetOneMedNet provides a platform for curating and exchanging real-world medical imaging and clinical data from healthcare provider networks to power life sciences, AI development, and academic research.
2 Pulse stories
Total Raised
$180M
Celea TherapeuticsOneMedNet
Last ValuationNot disclosed
Biotech
Sector
Biotech
2025
Founded
2006
Boston, MA
HQ
Eden Prairie, Minnesota
Private
Status
Public (ONMD)
Celea Therapeutics investors
RA Capital ManagementLeaps by BayerPureTech Health
OneMedNet investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Celea Therapeutics and OneMedNet.